Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

New Strategy for Fighting Viral Diseases

Ivanhoe Newswire


(Ivanhoe Newswire) -- A new anti-viral drug is showing promise in fighting viral diseases, including potential bioterrorism agents, according to a new study.

Scientists infected groups of guinea pigs with a virus similar to Lassa fever -- an endemic disease in portions of West Africa, where the disease is carried by rats. The Centers for Disease Control and Prevention lists Lassa fever as a Category A bioterrorism agent, the same class as Ebola.

Text Continues Below



In the study, half of the guinea pigs recovered completely from the virus when they were given the drug bavituximab, which was developed by researchers at the University of Texas Southwestern Medical Center. The studys authors said this is the first report of a therapeutic treatment being effective against advanced Lassa-like fever infections in animals.

In a second experiment, researchers gave both bavituximab and ribavirin, a common anti-viral medication, to infected guinea pigs, and 63 percent of the animals survived.

In other experiments, bavituximab treatment was also able to cure mice infected with cytomegalovirus, an opportunistic infection that afflicts transplant and AIDS patients.

The UT scientists developed bavituximab to bind to phosphatidylserine, a lipid molecule that flips from its normal position on the internal surface of a cell to the outside of the cell when the cell is infected by a virus. Dr. Phillip Thorpe, a professor of pharmacology at UT Southwestern and the studys lead author, predicted that the interaction with bavituximab would muster the bodys immune cells to attack and destroy the infected cells before the virus had a chance to replicate.

This approach reduces the ability of the virus to escape attack by a drug, Thorpe was quoted as saying.

Bavituximab is currently in clinical trials to treat patients with hepatitis C and it has been shown to be safe for patients.

Researches say this new approach to attacking viruses could lead to new ways of treating HIV, influenza, the herpes simplex virus, and viruses in the families of the small pox and rabies viruses.

SOURCE: Nature Medicine, December 2008

Sign up for a free weekly e-mail on Medical Breakthroughs called First to Know by clicking here.

This article was reported by Ivanhoe.com, who offers Medical Alerts by e-mail every day of the week. To subscribe, go to: http://www.ivanhoe.com/newsalert/.




Last updated 11/26/2008

Related Links
 border=
From Healthscout's partner site on diet & exercise, MyDietExercise.com
QUIZ: What's your ideal body weight?
QUIZ: Check your body mass index (BMI) online!
QUIZ: Rate your carbohydrate intake






About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy: Updated as of April 1, 2009  Terms of Service   Site Map
Advertising Policy